L92.0 L92.1 D86.3
Conditions
Interventions
Group 1: Between January 2024 and April 2026, a total of 8 patients with chronic, treatment-resistant granulomatous skin diseases were treated with topical JAK inhibitors as part of individual therape
therefore, after providing the patients with detailed information and based on the latest available scientific data, a decision was made to pursue individual therapeutic trials with topical JAK inhibi
scientific interest played no role in the decision.
Sponsors
Universitätsklinikum Düsseldorf- Klinik für Dermatologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Presence of a chronic, non-infectious granulomatous skin disease - Treatment with a topical JAK inhibitor (ruxolitinib or delgocitinib) - Treatment duration of at least 4 weeks - Application twice daily, as discussed with the patient
Exclusion criteria
Exclusion criteria: - Evidence that the patients objected to the use of their data for research purposes at any point during the study. - Treatment duration of less than 4 weeks or lack of compliance with the treatment regimen as documented in the medical history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Disease-specific outcomes following treatment with topical JAK inhibitors, as determined by disease-specific scoring systems (absolute and relative changes during treatment) over a maximum of 12 weeks - Granuloma Annulare Severity Index (GASI) - Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) - Necrobiosis Lipoidica Investigator Global Assessment (NL-IGA) and Necrobiosis Lipoidica Lesion Score (NLLS) - Proportion of responders (at least 50% improvement in the respective disease-specific score during treatment) vs. non-responders (less than 50% improvement in the respective disease-specific score during treatment and/or discontinuation or change of therapy due to lack of efficacy by the investigator and/or patient) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Patient satisfaction following treatment with topical JAK inhibitors, as measured by the Dermatology Life Quality Index (DLQI) - Occurrence of side effects - Duration of treatment or time until treatment change or escalation to systemic therapy | — |
Countries
Germany
Contacts
Public ContactRobin Springer
Universitätsklinikum Düsseldorf - Klinik für Dermatologie
Outcome results
None listed